Daniel Tobias Michaeli (Daniel Michaeli)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 21

Top Topics

Drug Administration

Low Density Lipoprotein

Renal Cell Carcinoma

Top Venues

BMJ (Clinical research ed.)

Clinical drug investigation

The European journal of health economics : HEPAC : health economics in prevention and care

Cardiovascular drugs and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. BMJ evidence-based medicine (2024)
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. Targeted oncology (2024)
Thomas Michaeli, Hendrik Jürges, Daniel Tobias Michaeli
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ (Clinical research ed.) 381 (2023)
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Tobias Boch, Julia Caroline Michaeli
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, Thomas Michaeli
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Clinical benefit, development, innovativeness, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations. Journal of the National Cancer Institute (2023)
Thomas Michaeli, Hendrik Jürges, Daniel Tobias Michaeli
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ (Clinical research ed.) 381 (2023)
Daniel Tobias Michaeli, Thomas Michaeli
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition. PharmacoEconomics (2023)
Thomas Michaeli, Hendrik Jürges, Daniel Tobias Michaeli
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ (Clinical research ed.) 381 (2023)
Thomas Michaeli, Hendrik Jürges, Daniel Tobias Michaeli
FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ (Clinical research ed.) 381 (2023)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular drugs and therapy (2022)
Daniel Tobias Michaeli, Sophia Stoycheva, Simon Mashudu Marcus, Wenjia Zhang, Julia Caroline Michaeli, Thomas Michaeli
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa. Clinical drug investigation 42 (4) (2022)
Daniel Tobias Michaeli, Thomas Michaeli
Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (35) (2022)
Daniel Tobias Michaeli, Mackenzie Mills, Panos G Kanavos
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Applied health economics and health policy 20 (5) (2022)
Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli
Socio-economic burden of disease: Survivorship costs for renal cell carcinoma. European journal of cancer care 31 (3) (2022)
Daniel Tobias Michaeli, Mackenzie Mills, Thomas Michaeli, Aurelio Miracolo, Panos G Kanavos
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. Investigational new drugs 40 (4) (2022)
Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli
Value drivers of development stage biopharma companies. The European journal of health economics : HEPAC : health economics in prevention and care 23 (8) (2022)
Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical drug investigation 42 (8) (2022)
Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli
Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors. Therapeutic innovation & regulatory science 56 (2) (2022)
Thomas Michaeli, Julia Michaeli, Daniel Tobias Michaeli
Testicular cancer follow-up costs in Germany from 2000 to 2015. Journal of cancer research and clinical oncology 147 (8) (2021)
Thomas Michaeli, Daniel Tobias Michaeli
Prostate cancer follow-up costs in Germany from 2000 to 2015. Journal of cancer survivorship : research and practice (2021)